🚀 VC round data is live in beta, check it out!
Anatolia Geneworks Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anatolia Geneworks and similar public comparables like AOTI, Svas Biosana, Envoy Medical, SMAIO and more.
Anatolia Geneworks Overview
About Anatolia Geneworks
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
Founded
2010
HQ
Employees
N/A
Website
Financials (FY)
EV
$59M
Anatolia Geneworks Financials
Anatolia Geneworks reported last fiscal year revenue of $16M and negative EBITDA of ($2M).
In the same fiscal year, Anatolia Geneworks generated $10M in gross profit, ($2M) in EBITDA losses, and had net loss of ($7M).
Anatolia Geneworks P&L
In the most recent fiscal year, Anatolia Geneworks reported revenue of $16M and EBITDA of ($2M).
Anatolia Geneworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $16M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 64% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (13%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (7%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (42%) | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Anatolia Geneworks Stock Performance
Anatolia Geneworks has current market cap of $55M, and enterprise value of $59M.
Market Cap Evolution
Anatolia Geneworks' stock price is $0.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59M | $55M | 0.0% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnatolia Geneworks Valuation Multiples
Anatolia Geneworks trades at 3.6x EV/Revenue multiple, and (26.7x) EV/EBITDA.
Anatolia Geneworks Financial Valuation Multiples
As of April 20, 2026, Anatolia Geneworks has market cap of $55M and EV of $59M.
Equity research analysts estimate Anatolia Geneworks' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anatolia Geneworks has a P/E ratio of (7.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV (current) | $59M | XXX | $59M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (26.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (50.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.7x | XXX | XXX | XXX |
| P/E | — | XXX | (7.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (14.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anatolia Geneworks Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Anatolia Geneworks Margins & Growth Rates
Anatolia Geneworks' revenue in the last fiscal year grew by 40%.
Anatolia Geneworks Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 78% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Anatolia Geneworks Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anatolia Geneworks | XXX | XXX | XXX | XXX | XXX | XXX |
| AOTI | XXX | XXX | XXX | XXX | XXX | XXX |
| Svas Biosana | XXX | XXX | XXX | XXX | XXX | XXX |
| Envoy Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| SMAIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Tobii | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anatolia Geneworks M&A Activity
Anatolia Geneworks acquired XXX companies to date.
Last acquisition by Anatolia Geneworks was on XXXXXXXX, XXXXX. Anatolia Geneworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Anatolia Geneworks
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnatolia Geneworks Investment Activity
Anatolia Geneworks invested in XXX companies to date.
Anatolia Geneworks made its latest investment on XXXXXXXX, XXXXX. Anatolia Geneworks invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Anatolia Geneworks
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anatolia Geneworks
| When was Anatolia Geneworks founded? | Anatolia Geneworks was founded in 2010. |
| Where is Anatolia Geneworks headquartered? | Anatolia Geneworks is headquartered in Turkey. |
| Is Anatolia Geneworks publicly listed? | Yes, Anatolia Geneworks is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Anatolia Geneworks? | Anatolia Geneworks trades under ANGEN ticker. |
| When did Anatolia Geneworks go public? | Anatolia Geneworks went public in 2021. |
| Who are competitors of Anatolia Geneworks? | Anatolia Geneworks main competitors are AOTI, Svas Biosana, Envoy Medical, SMAIO. |
| What is the current market cap of Anatolia Geneworks? | Anatolia Geneworks' current market cap is $55M. |
| What is the current revenue of Anatolia Geneworks? | Anatolia Geneworks' last fiscal year revenue is $16M. |
| What is the current EV/Revenue multiple of Anatolia Geneworks? | Current revenue multiple of Anatolia Geneworks is 3.6x. |
| Is Anatolia Geneworks profitable? | No, Anatolia Geneworks is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.